Success Metrics

Active Trials
3(75%)

Phase Distribution

Ph phase_2
1
25%
Ph phase_4
1
25%
Ph phase_3
2
50%

Phase Distribution

0

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
2(50.0%)
Phase 4Post-market surveillance
1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

4

all time

Status Distribution
Active(3)
Other(1)

Detailed Status

Recruiting2
Active, not recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
3
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Phase 21 (25.0%)
Phase 32 (50.0%)
Phase 41 (25.0%)

Trials by Status

active_not_recruiting125%
recruiting250%
unknown125%

Recent Activity

3 active trials
Showing 4 of 4
recruitingphase_4

Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases

NCT07087912
recruitingphase_3

Butantan-DV Vaccine in Elderly Populations (DEN-04-IB)

NCT06891950
active_not_recruitingphase_3

Phase III Trial to Evaluate Efficacy and Safety of a Tetravalent Dengue Vaccine

NCT02406729
unknownphase_2

Phase II Trial to Evaluate Safety and Immunogenicity of a Dengue 1,2,3,4 (Attenuated) Vaccine

NCT01696422

Clinical Trials (4)

Showing 4 of 4 trials
NCT07087912Phase 4

Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases

Recruiting
NCT06891950Phase 3

Butantan-DV Vaccine in Elderly Populations (DEN-04-IB)

Recruiting
NCT02406729Phase 3

Phase III Trial to Evaluate Efficacy and Safety of a Tetravalent Dengue Vaccine

Active Not Recruiting
NCT01696422Phase 2

Phase II Trial to Evaluate Safety and Immunogenicity of a Dengue 1,2,3,4 (Attenuated) Vaccine

Unknown

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4